STRO insider trading
NasdaqGM HealthcareSUTRO BIOPHARMA, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About SUTRO BIOPHARMA, INC.
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Company website: www.sutrobio.com
STRO insider activity at a glance
FilingIQ has scored 399 insider transactions for STRO since Oct 1, 2018. The most recent filing in our index is dated Mar 4, 2026.
Across the full history, 10 open-market purchases
and 26 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on STRO insider trades is 60.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Top insiders trading STRO
13F funds holding STRO
Frequently asked
- How many insider trades does FilingIQ track for STRO?
- FilingIQ tracks 399 Form 4 insider transactions for STRO (SUTRO BIOPHARMA, INC.), covering filings from Oct 1, 2018 onwards. 36 of those were filed in the last 90 days.
- Are STRO insiders net buyers or net sellers?
- Across the full Form 4 history for STRO, 10 transactions (3%) were open-market purchases and 26 (7%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does STRO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is STRO in?
- SUTRO BIOPHARMA, INC. (STRO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $322.84M.
Methodology & sources
Every STRO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.